Objective To investigate the expression of Ki67 in benign and malignant breast tumor, and to explore the correlation between the expression of Ki67 and pathologic response to neoadjuvant chemotherapy in primary breast cancer. Methods Using immunohistochemistry, the expression of Ki67 in 49 paticnts with primary breast cancer (the study group) before chemotherapy was investigated, and compared with that in 20 breast fibroadcnoma (the control group). The correlation between the expression of Ki67 and pathologic response to neoadjuvant chemotherapy was analyzed. Results The positive rate of Ki67 in breast cancer tissues was 44.90% (22/49), which was significantly higher than 10.0% (2/20) in breast fibroadenoma tissues (P=0.006). Xo correlation between Ki67 expression and pathologic response to neoadjuvant chemotherapy was found. The expression of Ki67 in breast cancer tissues was not correlated with patients' age, menstrual status, tumor size and lymph node condition. Patients younger than 50 years old had a better therapeutic efficacy, compared those older than 50 years old, after receiving neoadjuvant chemotherapy (P=0.037). And the patients who have a tumor size smaller than 2 cm had higher probability to achieve pathologic completely release (P=0.039). Conclusion The expression of Ki67 in benign and malignant breast tumor showed significant difference. Patients younger than 50 years old or with a tumor size smaller than 2 cm benefit more than others from neoadjuvant chemotherapy.%目的 探讨Ki67在乳腺良恶性肿瘤中表达的差异及其表达与乳腺癌新辅助化疗及临床病理参数的相关性.方法 采用免疫组化的方法检测49例原发性乳腺癌在接受新辅助化疗之前肿瘤组织中Ki67的表达,与20例乳腺纤维腺瘤中Ki67的表达进行对比,探讨Ki67表达与新辅助化疗病理疗效的相关性,同时分析新辅助化疗疗效与临床病理参数间的关系.结果 乳腺癌组织中Ki67的阳性率为44.90％ (22/49),乳腺纤维腺瘤中Ki67的表达率为10.0％ (2/20),Ki67在乳腺良恶性肿瘤组织中的表达差异有统计学意义(P=0.006); Ki67表达与病理有效率之间无相关性.乳腺癌组织中Ki67表达与患者的年龄、绝经与否、肿瘤大小、淋巴结状态无关.小于50岁的患者接受新辅助化疗的化疗疗效优于50岁以上的患者(P=0.037),肿瘤直径小于2 cm的患者更易通过新辅助化疗取得病理学完全缓解(P=0.039).结论 Ki67在乳腺良恶性肿瘤中表达差异有统计学意义,小于50岁或肿瘤直径小于2cm的患者更能从新辅助化疗中受益.
展开▼
